Bristol-Myers Squibb Co. (BMY)

47.79
0.42 0.87
NYSE : Health Technology
Prev Close 48.21
Open 48.28
Day Low/High 47.71 / 48.68
52 Wk Low/High 44.30 / 63.69
Volume 11.52M
Avg Volume 15.11M
Exchange NYSE
Shares Outstanding 1.64B
Market Cap 77.80B
EPS 3.00
P/E Ratio 15.15
Div & Yield 1.64 (3.42%)

Today's Takeaways and Observations (Early Edition)

"I would describe today's market action as "benign." And that applies to almost every asset class." -- Kass Diary 104 trading sessions without a one percent drop in the indices. "Don't Think the Machines Could Turn to Selling? You've Forgotten 1987....

Cramer: Don't Give the Fed Credit

Cramer: Don't Give the Fed Credit

Most of the 10 best stocks of the bull market did it their way.

Takeaways and Observations

  "Wishin' and hopin' And thinkin' and prayin'..."  -- Dusty Springfield, Wishin' and Hopin'  The gap from last week's presidential speech was filled this afternoon.  I am more negative than most and more negative than I have been in a while.  Liter...

Cowen Health Care Conf.

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy

In a 24-week trial of 22 patients, OncoSec saw a 41% response rate

Is This the Start of a Downturn?

Is This the Start of a Downturn?

There has been a very narrow trading range and a lack of price movement.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Cramer: I'll Give You the Key to the Rally

Cramer: I'll Give You the Key to the Rally

You have to keep up with the sector rotations.

Takeaways and Observations

"Bull markets are born on pessimism, grow on skepticism, mature on optimism and die on euphoria." -- Sir John Templeton  DuPont (still on my Best Ideas List) and 3M accounted for 110% of today's gain in the Dow Jones Industrial Average.  It was the ...

Cramer: Is the Market Playing 'The Price Is Wrong'?

Cramer: Is the Market Playing 'The Price Is Wrong'?

These may be uncharted waters, but they're not necessarily expensive.

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Cramer: Buyers for Bristol-Myers Are Few and Far Between

Icahn may have a tough time finding interest in this behemoth.

Jim Cramer Talks Tesla, TJX, Square, Fitbit and National Margarita Day!

Jim Cramer Talks Tesla, TJX, Square, Fitbit and National Margarita Day!

TheStreet's Jim Cramer comments on Wednesday's most talked about stocks.

Wake Up Wall Street: Dow Jones Secures Eighth Straight Day of Gains

Wake Up Wall Street: Dow Jones Secures Eighth Straight Day of Gains

Here are 5 things you must know before the market opens Wednesday.

Toll Brothers Beats Expectations, Icahn Buys Stake in Drug Maker

Toll Brothers Beats Expectations, Icahn Buys Stake in Drug Maker

Toll Brothers TOL says the average price of a home it built declined, due to the cost of building materials.

Takeaways and Observations

  Every single market indicator I look at is overbought.  But it's likely that shorts and underperformers are buoying stocks.  Some are at the most overbought in decades.  The bond market is clearly not as sanguine on economic growth/corporate profi...

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Activist Investors Shake Up the Boards at Tiffany & Bristol-Myers Squibb

Jana Partners are placing three members on Tiffany's board.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Your Burning Biotech Questions Answered

Your Burning Biotech Questions Answered

We explore whether the biotech rally can continue and if Gilead Sciences has bottomed.

Health Care ETF Has Been Ailing

Health Care ETF Has Been Ailing

You might want to review your holdings in the sector.

Takeaways and Observations

I started the day with a discussion of the new administration's policies and why I believe there are headwinds to their passage over the next few months or quarters.  I covered last evening's Procter & Gamble short for a profit.  "For Traders Only."...

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Cramer: Allergan Is the New Pharma Growth Stock

Cramer: Allergan Is the New Pharma Growth Stock

Jim Cramer compares Allergan's growth to other pharma stocks.

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Cramer: Trump's Carrot-Stick Approach Doesn't Make Pharma Any More Attractive

Two industries should largely be avoided under this administration: pharma and retail.

7 Things to Watch in Biotech Now

7 Things to Watch in Biotech Now

M&A, drug approvals and Trump are all on my watch list.

Bristol-Myers numbers cut at Jefferies

My Takeaways and Observations

"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...

Jim Cramer: Bristol-Myers Needs to Slim Down

Jim Cramer: Bristol-Myers Needs to Slim Down

Bristol-Myers Squibb needs to reorganize itself in what is now a challenging environment, says Jim Cramer.

Dow May Linger at 20K for a While

Dow May Linger at 20K for a While

I am reluctant to call this a breakout, and am willing to sit back and wait.

Bristol-Myers numbers cut at BMO